
Biohaven Pharmaceutical Holding Company Ltd. BHVN
$ 9.15
-6.63%
Quarterly report 2022-Q2
added 12-16-2023
Biohaven Pharmaceutical Holding Company Ltd. General and Administrative Expenses 2011-2026 | BHVN
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Biohaven Pharmaceutical Holding Company Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 714 M | 462 M | 134 M | 34.6 M | 18.1 M | 5.11 M | 2.14 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 714 M | 2.14 M | 196 M |
Quarterly General and Administrative Expenses Biohaven Pharmaceutical Holding Company Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 227 M | - | 165 M | 170 M | 160 M | 122 M | 120 M | 125 M | 95.6 M | 69 M | 28.8 M | 23.2 M | 13.5 M | 10.1 M | 7.57 M | 9.06 M | 7.86 M | 5.61 M | 4.57 M | 4.2 M | 3.76 M | 2.45 M | 920 K | 1.12 M | 613 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 227 M | 613 K | 57.3 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioNTech SE
BNTX
|
286 M | $ 91.28 | 0.11 % | $ 27.2 B | ||
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
900 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | ||
|
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | ||
|
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | ||
|
Akari Therapeutics, Plc
AKTX
|
9.28 M | $ 3.54 | -20.81 % | $ 238 B | ||
|
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
1.21 B | $ 330.34 | 3.6 % | $ 43.3 B | ||
|
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
10.9 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | ||
|
Evogene Ltd.
EVGN
|
7.25 M | $ 0.79 | 1.22 % | $ 27.9 M | ||
|
Atreca
BCEL
|
31.5 M | - | -11.76 % | $ 5.79 M | ||
|
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | ||
|
argenx SE
ARGX
|
308 M | $ 748.25 | 0.25 % | $ 25 B | ||
|
Завод ДИОД
DIOD
|
19.7 M | - | - | - | ||
|
Фармсинтез
LIFE
|
24.1 M | - | - | - | ||
|
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | ||
|
Aptorum Group Limited
APM
|
5.41 M | $ 0.89 | -4.33 % | $ 4.85 M | ||
|
Applied Therapeutics
APLT
|
20.6 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | ||
|
Teligent, Inc.
TLGT
|
23.4 M | - | -13.85 % | $ 16.1 M | ||
|
AbbVie
ABBV
|
14 B | $ 206.69 | -1.01 % | $ 366 B | ||
|
Aquestive Therapeutics
AQST
|
79.8 M | $ 4.09 | -0.97 % | $ 437 M | ||
|
Aravive
ARAV
|
13 M | - | -13.39 % | $ 1.45 M | ||
|
Viela Bio, Inc.
VIE
|
60.2 M | - | - | $ 2.91 B | ||
|
AbCellera Biologics
ABCL
|
83.2 M | $ 3.39 | -3.69 % | $ 1.01 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
46.1 M | $ 8.22 | 2.37 % | $ 225 M | ||
|
Ardelyx
ARDX
|
337 M | $ 5.97 | 0.51 % | $ 1.44 B | ||
|
Genmab A/S
GMAB
|
661 M | $ 27.75 | 0.91 % | $ 17.6 B | ||
|
Cerevel Therapeutics Holdings
CERE
|
113 M | - | - | $ 7.29 B | ||
|
Grifols, S.A.
GRFS
|
1.06 B | $ 8.23 | -0.12 % | $ 6.83 B | ||
|
Akebia Therapeutics
AKBA
|
107 M | $ 1.32 | -4.35 % | $ 339 M |